Breaking News! 2026 American Diabetes Association(ADA) : CGM Promoted to "Key Engine" in Diabetes Management!

As the most influential "bellwether" in the global diabetes field, the latest edition of the Standards of Care in Diabetes—2026 ^[1] (hereinafter referred to as the 2026 ADA Guidelines) has been officially released recently.  

In the 2026 ADA Guidelines, continuous glucose monitoring (CGM) is placed in an unprecedentedly important position. Not only has its recommendation strength been further upgraded, but its clinical positioning, target population, and application scenarios have also been systematically reorganized and defined, sending a clear signal: blood glucose management is fully moving from the "point-value era" to the "dynamic era".  

This article will focus on the 5 recommended points related to CGM in the 2026 ADA Guidelines, helping you understand the clinical logic and practical value behind this round of updates. 

Point1：From Glycated Hemoglobin (HbA1c) to CGM：Establishing a Framework for Personalized Glucose Management

HbA1c has been regarded as the “gold standard” in the traditional blood glucose monitoring system for a long time.It reflects the average blood glucose level over the past 2 to 3 months,yet it has an unavoidable limitation：it only provides you the “Mean”, without revealing the process！

Once CGM appears, it unlocks the information obscured by the“Mean”.By monitoring the blood glucose data every 3 minutes,CGM reflects the blood glucose trends continuously and comprehensively to supplement the key information that HbA1c cannot provide. 

Therefore,2026 ADA Guidelines state that blood glucose management goal is no longer be 'one-size-fits-all'. Instead, individualized CGM management targets should be established based on the patient's health status, treatments, and risks ( Figure 6.1 in the 2026 ADA Guidelines ).

 Figure. Individualized HbA1c and CGM Treatment Targets for Adults (Non-Pregnant)

Point2：Breaking CGM Boundaries, Expanding Population Coverage to a Historic High

CGM achieved a breakthrough in the 2025 ADA Guidelines. Patients with type 2 diabetes mellitus (T2DM) were formally included in non-insulin therapy for the first time. The guidelines also covers all patients with type 1 diabetes mellitus (T1DM) ,as well as adolescents and adults with either T1DM or T2DM, without restrictions by specific treatment regimens.This marks that CGM has evolved from a“support tools for the specific populations” to a “basic blood glucose management tool for the general public”.

The 2026 ADA Guidelines further broaden this point. In section 7.15, the 2026 ADA Guidelines explicitly state that CGM is recommended for children, adolescents, and adults with diabetes at the onset of the disease and at any stage of its progression, including insulin therapy, non-insulin therapies that may lead to hypoglycemia, and any diabetes treatment that can be managed with CGM. This indicates that CGM is evolving into a universal glycemic management tool covering multiple treatment pathways and spanning the entire disease course, becoming a critical infrastructure for modern precision diabetes management.

This recommendation is based on a solid foundation of evidence-based medicine. The guidelines cites multiple randomized controlled trials on the use of CGM, which demonstrate that patients who consistently and regularly use CGM achieve clear and stable overall benefits in lowering HbA1c and/or reducing hypoglycemic. Notably, these clinical benefits conferred by CGM are unaffected by age, gender, education level, income, or baseline diabetes characteristics, indicating its broad applicability and significant universal value.

Furthermore, the updated evidence shows a consistent and clear pattern of benefit across different populations:

l Children with T1DM：The use of CGM reduces the incidence of hypoglycemia significantly; behavioral support interventions for parents of young children wearing CGM not only help further reduce the risk of hypoglycemia but also alleviate parental concerns about hypoglycemia and the psychological burden associated with diabetes.

l Adolescent and Young Adult Patients with T1DM：The use of real-time CGM leads to significant improvement in HbA1c management.

l Patients with T2DM：Whether treated with insulin or non-insulin therapy, CGM consistently demonstrates stable and clear clinical benefits.

The guidelines further clarify the preferred pathway for insulin infusion technology based on these. 2026 ADA Guidelines state that the automated insulin delivery (AID) system should be the preferred insulin infusion regimen,which is applicable to patients with T1DM, adults and children with T2DM requiring multiple daily insulin injections, individuals on continuous subcutaneous insulin infusion (CSII) or sensor-enhanced insulin pump therapy, and the patients with other insulin deficiency diabetes.At the same time,the guidelines emphasizes that essential technical support(CGM ,CSII, smart insulin pens and AID) should be provided to children and adolescents in school settings. This ensures safe and continuous blood glucose monitoring during learning and daily activities, as well as appropriate insulin management, thereby reducing blood glucose fluctuations and the risk of hypoglycemia.

Point3：Strengthening CGM Recommendations for Special Populations and Improving Treatment Safety and Efficacy

For the elderly patients with diabetes who use insulin ,the guidelines recommend that CGM should be employed to improve glycemic outcomes, reduce hypoglycemia, and alleviate the treatment burden.It conveys an important message: CGM is not only a "glycemic control tool" but also a "safety tool." In elderly patients with cognitive decline or physical limitations, CGM reduce management complexity and minimize the risk of severe hypoglycemia through continuous monitoring and trend alerts, thereby enhancing treatment safety and operability.

In the women with gestational diabetes mellitus (GDM), the guidelines also provide confirmation: CGM facilitates the achievement of glycemic control targets (e.g., TIR, TAR) and HbA1c targets in pregnant women with T1DM, and may also be beneficial for other types of GDM.This suggests that during pregnancy, a highly dynamic physiological phase, CGM captures blood glucose fluctuations more sensitively, providing refined and real-time management support to address the progressively worsening physiological insulin resistance.

Point4：From “Post-Event Remediation” to “Early Warning”, CGM Rebuilds Hypoglycemia Management!

Hypoglycemia, particularly grade 2 [blood glucose <54 mg/dL (≤3.0 mmol/L)] and grade 3 (severe events requiring assistance) hypoglycemia , is the most refractory and high-risk barriers in glycemic management.CGM transforms hypoglycemia from a passive “post-event” occurrence into a risk signal that can be identified early and intervened proactively through real-time glucose monitoring, trend arrows, and early warning systems.

l Identification of unconscious hypoglycemia: For patients with unconscious hypoglycemia or impaired consciousness, CGM is an essential safety tool. Studies have shown that continuous use of CGM significantly reduces the risk of grade 3 severe hypoglycemia.

l Night protection: The real-time alert function of CGM effectively prevents “hypoglycemia during sleep”, providing continuous security for patients and their families.

l Reducing treatment fear: By simultaneously reducing the actual risk of hypoglycemia and alleviating patients' subjective fear of hypoglycemia, CGM empowers users to adjust insulin doses with greater confidence, thereby approaching the ideal glycemic target under safer conditions.

Point5：Key to Successful CGM Implementation: Education, Continuous Supply, and Skin Care Management

Diabetes technology is advancing rapidly, with new methods and tools emerging annually. However, researches often struggles to keep pace—by the time a study is completed, a new version of the device or digital solution may already be available. Among these, the patient remains the most critical factor.

Merely possessing devices or applications can not automatically improve health outcomes . Only when patients use them correctly and consistently can they achieve positive results. This highlights the critical role of healthcare teams: assisting patients in selecting appropriate technologies and supporting their efficient and safe application through continuous education and training, thereby achieving optimal health management.

l Initial and continuing education and training：

Ensure that patients and caregivers receive comprehensive training on device use, data interpretation, and troubleshooting;

Regularly assess educational needs, especially when treatment goals are not met.

l Ensure continues supply of consumables

Emphasize that CGM should be used daily to maximize benefits;

Healthcare teams should assist patients in resolving insurance and supply issues to minimize discontinuations and avoid data gaps.

l Assessment and management of skin reactions:

Skin irritation or allergic reactions are common reasons for discontinuation of CGM use;

Proactive inquiries and solutions should be provided, such as the use of skin protective films, rotation of wearing sites, or consideration of devices with different adhesives.

Summary

In a word，the 2026 ADA Guidelines send a clear message: blood glucose management is transitioning from a “single metric” approach to a “multidimensional, dynamic, and individualized decision-making” framework.

The guidelines further establishes the foundational role of CGM in modern diabetes management by emphasizing the combined interpretation of HbA1c and CGM indicators, systematically expanding the applicable population for CGM, and reinforcing recommendations for high-risk and special populations. It also explicitly states that CGM can only achieve sustainable clinical benefits under the conditions of standardized education, continuous and accessible device supply, and comprehensive usage support.

References：

[1] American Diabetes Association Professional Practice Committee for Diabetes*; 7. Diabetes Technology: Standards of Care in Diabetes—2026. Diabetes Care 1 January 2026; 49 (Supplement_1): S150–S165. https://doi.org/10.2337/dc26-S007